View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/FDA | RIN: 0910-AG04 | Publication ID: Fall 2007 |
Title: ●Amendment to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals | |
Abstract: The Food and Drug Administration (FDA) is amending certain sections of 21 CFR parts 210 and 211 as the first phase of an incremental approach to modifying the current good manufacturing practice (CGMP) regulations for finished pharmaceuticals in 21 CFR parts 210 and 211. We are amending the regulations to modernize or clarify some of the CGMP requirements, as well as harmonize some of the CGMP requirements with those of other foreign regulators and other FDA regulations. These amendments are also consistent with current industry practice. We are taking this action as part of our continuing effort to revise outdated regulations without diminishing public health protection. | |
Agency: Department of Health and Human Services(HHS) | Priority: Routine and Frequent |
RIN Status: First time published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: No | Unfunded Mandates: No |
CFR Citation: 21 CFR 210 to 211 | |
Legal Authority: 21 USC 321 21 USC 351 to 352 21 USC 355 21 USC 360b 21 USC 371 21 USC 374 42 USC 216 42 USC 262 42 USC 263a to 264 |
Legal Deadline:
None |
|||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Federalism: No | |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Jessica Tave Regulatory Counsel Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 1401 Rockville Pike, Suite 200N, HFM-600, Rockville, MD 20852 Phone:301 827-6190 |